Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 1139 first isolates · ED · Cystitis (lower UTI) · 2025-09-07 → 2026-09-06
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (80 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (6 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
87 %
n = 117
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
76 %
n = 117
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
85 %
n = 117
ciprofloxacin CIP
trend · Escherichia coli
78 %
82 %
n = 117
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
80 %
n = 117
ceftriaxone CRO
trend · Escherichia coli
76 %
79 %
n = 117
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
69 %
n = 117
71 %
74 %
n = 117
52 %
45 %
n = 117
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
9 %
n = 117
5 %
9 %
n = 117
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 117

Most likely organisms for this profile

Escherichia coli
54 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
6 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.